CliffBio
small molecule

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

Loss of exclusivity—loss of exclusivity
CompanyTaro Pharmaceutical Industries →See this company's full patent-cliff portfolio

Drug detail

Brand nameBUTALBITAL, ACETAMINOPHEN AND CAFFEINE
Active ingredientACETAMINOPHEN; BUTALBITAL; CAFFEINE
Strength300MG;50MG;40MG
Dosage formCAPSULE
RouteORAL
ModalitySmall molecule
FDA approvalJuly 2020
Marketing statusRX

More from Taro Pharmaceutical Industries

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.